News

Tubulis Adds Steve Kelsey as Independent Director to its Advisory Board

Tubulis Unveils Alco5 Conjugation Platform’s Ability to Expand ADC Payload Scope in Nature Communications

Tubulis Appoints Charles Fuchs, MD as Chief Medical Officer to Lead Clinical Strategy and Pipeline Development

Tubulis to Present at the 44th Annual J.P. Morgan Healthcare Conference

Tubulis Announces Second Closing of Series C Bringing Total Raised to €344M (US $401M)

Tubulis Presents First Clinical Data from Phase I/IIa Trial for TUB-040 in Platinum-Resistant Ovarian Cancer (PROC) at ESMO 2025

Tubulis Raises €308 Million Series C to Accelerate Clinical Development of Lead ADC Candidate TUB-040 and Expand Pipeline

Tubulis to Present First Phase I/IIa Trial Data for ADC CandidateTUB-040 in Platinum-resistant Ovarian Cancer in Late-breaking Oral Presentation at ESMO 2025

Tubulis Strengthens Leadership Team with Appointment of Halley Gilbert as Chief Legal and Operating Officer

Tubulis Achieves Key Milestone in BMS Strategic License Agreement as First Collaboration Tubutecan ADC Enters the Clinic

Tubulis Strengthens Executive Leadership with Appointment of Matthew Norkunas as Chief Financial Officer and President of Tubulis Inc.

Tubulis Announces First Patient Dosed in Phase I/IIa Trial Evaluating ADC TUB-030 in Advanced Solid Tumors

Tubulis to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Gilead and Tubulis Enter into Exclusive Option and Licence Agreement to Develop ADC Candidate for Select Solid Tumor Target

Fierce Biotech Names Tubulis a “Fierce 15” Biotech Company of 2024

Tubulis Receives FDA Fast Track Designation for Antibody-Drug Conjugate Candidate TUB-040 in Platinum-resistant Ovarian Cancer

Tubulis Doses First Patient in Phase I/IIa Trial Investigating ADC Candidate TUB-040 in Ovarian Cancer and Lung Adenocarcinoma

Tubulis Presents Preclinical Data for Solid Tumor Targeting ADC Candidates TUB-030 and TUB-040 Demonstrating Superior Efficacy Profile and a Wide Therapeutic Window at the AACR Annual Meeting 2024

Tubulis Closes Upsized €128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline

Tubulis to Present Preclinical Proof-of-Concept Data for Two Lead ADC Candidates Targeting Solid Tumors at the AACR Annual Meeting 2024